2,603 reports of this reaction
1.8% of all BORTEZOMIB reports
#13 most reported adverse reaction
NEUTROPENIA is the #13 most commonly reported adverse reaction for BORTEZOMIB, manufactured by Takeda Pharmaceuticals America, Inc.. There are 2,603 FDA adverse event reports linking BORTEZOMIB to NEUTROPENIA. This represents approximately 1.8% of all 141,037 adverse event reports for this drug.
Patients taking BORTEZOMIB who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is a less commonly reported adverse event for BORTEZOMIB, but still significant enough to appear in the safety profile.
In addition to neutropenia, the following adverse reactions have been reported for BORTEZOMIB:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 2,603 FDA reports for BORTEZOMIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 1.8% of all adverse event reports for BORTEZOMIB, making it a notable side effect.
If you experience neutropenia while taking BORTEZOMIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.